Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 450-457

  Kontos, Christos K ^a   Mavridis, Konstantinos ^a   Talieri, Maroulio ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Colorectal cancer; Gastric cancer; Kallikrein splice variants; Molecular tumour markers; Pancreatic carcinoma

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN 1; KALLIKREIN 10; KALLIKREIN 11; KALLIKREIN 12; KALLIKREIN 13; KALLIKREIN 15; KALLIKREIN 4; KALLIKREIN 5; KALLIKREIN 6; KALLIKREIN RELATED PEPTIDASE; NEUROPSIN; SERINE PROTEINASE; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CLINICAL DECISION MAKING; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; GENETIC ASSOCIATION; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR GROWTH;

ALTERNATIVE SPLICING; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DECISION MAKING; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PEPTIDE HYDROLASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883240236     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-11-0791     Document Type: Article

References (62)

1. Yousef GM, Kopolovic AD, Elliott MB, et al. Genomic overview of serine proteases. Biochem Biophys Res Commun 2003; 305: 28-36.
2. Diamandis EP, Yousef GM, Luo LY, et al. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000; 11: 54-60.
3. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001; 22: 184-204.
4. Clements JA, Willemsen NM, Myers SA, et al. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312.
5. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
6. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004; 2: 257-280.
7. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890.
8. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
9. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391: 505-511.
10. Scorilas A, Mavridis K. Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead. J Surg Oncol 2012; 105: 223-224.
11. Bayani J, Diamandis EP. The physiology and pathobiology of human kallikreinrelated peptidase 6 (KLK6). Clinical chemistry and laboratory medicine: CCLM / FESCC 2012; 50: 211-233.
12. Nagahara H, Mimori K, Utsunomiya T, et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res 2005; 11: 6800-6806.
13. Kim JJ, Kim JT, Yoon HR, et al. Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer. Tumour Biol 2012; 33: 731-738.
14. Nobili S, Bruno L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 2011; 17: 290-299.
15. Sawant S, Snyman C, Bhoola K. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int Immunopharmacol 2001; 1: 2063-2080.
16. Zhu B, Lu L, Cai W, et al. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007; 6: 3297-3306.
17. Huang W, Zhong J, Wu LY, et al. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett 2007; 251: 78-85.
18. Huang W, Tian XL, Wu YL, et al. Suppression of gastric cancer growth by baculovirus vector-mediated transfer of normal epithelial cell specific-1 gene. World J Gastroenterol 2008; 14: 5810-5815.
19. Feng B, Xu WB, Zheng MH, et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol 2006; 21: 1596-1603.
20. Li M, Zhao ZW, Zhang Y, et al. Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer. Dig Dis Sci 2011; 56: 698-706.
21. Yousef GM, White NM, Michael IP, et al. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour Biol 2005; 26: 227-235.
22. Zhao EH, Shen ZY, Liu H, et al. Clinical significance of human kallikrein 12 gene expression in gastric cancer. World J Gastroenterol 2012; 18: 6597-6604.
23. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem 2012; 393: 301-317.
24. Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 2010; 6: 269-285.
25. Yousef GM, Borgono CA, White NM, et al. In silico analysis of the human kallikrein gene 6. Tumour Biol 2004; 25: 282-289.
26. Shinmura K, Tao H, Yamada H, et al. Splice-site genetic polymorphism of the human kallikrein 12 (KLK12) gene correlates with no substantial expression of KLK12 protein having serine protease activity. Human mutation 2004; 24: 273-274.
27. Konstantoudakis G, Florou D, Mavridis K, et al. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem 2010; 43: 1205-1211.
28. Florou D, Mavridis K, Scorilas A. The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumour Biol 2012; 33: 2069-2078.
29. Wen YG, Wang Q, Zhou CZ, et al. Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry. J Surg Oncol 2011; 104: 516-524.
30. Ramsay AJ, Reid JC, Adams MN, et al. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol Chem 2008; 389: 653-668.
31. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-282.
32. Nishibori M, Mori S, Takahashi HK. Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. J Pharmacol Sci 2005; 97: 25-30.
33. Caliendo G, Santagada V, Perissutti E, et al. Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development. J Med Chem 2012; 55: 6669-6686.
34. Gratio V, Beaufort N, Seiz L, et al. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am J Pathol 2010; 176: 1452-1461.
35. Gratio V, Loriot C, Virca GD, et al. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signalling pathway in colon cancer cells. Am J Pathol 2011; 179: 2625-2636.
36. Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med 2012; 50: 1877-1891.
37. Talieri M, Li L, Zheng Y, et al. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer 2009; 100: 1659-1665.
38. Yu X, Tang HY, Li XR, et al. Over-expression of human kallikrein 11 is associated with poor prognosis in patients with low rectal carcinoma. Med Oncol 2010; 27: 40-44.
39. Devetzi M, Trangas T, Scorilas A, et al. Parallel overexpression and clinical significance of kallikrein-related peptidases 7 and 14 (KLK7 & KLK14) in colon cancer. Thromb Haemost 2013; 109: 716-725.
40. Talieri M, Alexopoulou DK, Scorilas A, et al. Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol 2011; 32: 737-744.
41. Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11: 2889-2893.
42. Kontos CK, Chantzis D, Papadopoulos IN, et al. Quantitative expression analysis and prognostic significance of KLK4 mRNA expression in colon cancer. In: Schmitt M, Fritz H, Sommerhoff CP, et al., editors. 3rd International Symposium on Kallikreins and Kallikrein-Related Peptidases 2009 August 30-September 2, 2009; Munich, Germany: Hieronymus Druck und Verlag; 2009. p. 86.
43. Kontos CK, Chantzis D, Papadopoulos IN, et al. Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Lett 2013; 330: 106-112.
44. Talieri M, Mathioudaki K, Prezas P, et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost 2009; 101: 741-747.
45. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379.
46. Johnson SK, Ramani VC, Hennings L, et al. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 2007; 109: 1811-1820.
47. Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun 2008; 369: 1169-1173.
48. Lee CY, Marzan D, Lin G, et al. alpha2 Integrin-Dependent Suppression of Pancreatic Adenocarcinoma Cell Invasion Involves Ectodomain Regulation of Kallikrein-Related Peptidase-5. J Oncol 2011; 2011: 365651.
49. Ramani VC, Hennings L, Haun RS. Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer 2008; 8: 373.
50. Pignatelli M, Ansari TW, Gunter P, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994; 174: 243-248.
51. Chidgey M, Dawson C. Desmosomes: a role in cancer? Br J Cancer 2007; 96: 1783-1787.
52. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-442.
53. Iakovlev V, Siegel ER, Tsao MS, et al. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2012; 21: 1135-1142.
54. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63: 8614-8622.
55. Hustinx SR, Cao D, Maitra A, et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 2004; 3: 1254-1261.
56. Yousef GM, Borgono CA, Popalis C, et al. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res 2004; 24: 43-51.
57. Linardoutsos D, Avgeris M, Bramis J, et al. Expression analysis of kallikrein-related peptidase 4 gene (KLK4) in pancreatic cancer. In: Scorilas A, editor. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases; 2011; Rhodes, Greece; 2011.
58. Lavergne E, Petit-Courty A, Vallet A, et al. Expression pattern of the kallikreinrelated peptidase (KLK) gene family in normal and pathological human liver. In: Scorilas A, editor. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases; 2011; Rhodes, Greece; 2011.
59. Lu CY, Hsieh SY, Lu YJ, et al. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. Genes Chromosomes Cancer 2009; 48: 1057-1068.
60. Lu L, Yang Z, Zhu B, et al. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 2007; 257: 97-106.
61. Dlamini Z, Bhoola KD. Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol 2005; 58: 915-922.
62. Dlamini Z, Raidoo D, Bhoola K. Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. Immunopharmacology 1999; 43: 303-310.